These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

315 related items for PubMed ID: 19411847

  • 1. Amyloid deposits: protection against toxic protein species?
    Treusch S, Cyr DM, Lindquist S.
    Cell Cycle; 2009 Jun 01; 8(11):1668-74. PubMed ID: 19411847
    [Abstract] [Full Text] [Related]

  • 2. Amyloid in neurodegenerative diseases: friend or foe?
    Wolfe KJ, Cyr DM.
    Semin Cell Dev Biol; 2011 Jul 01; 22(5):476-81. PubMed ID: 21458579
    [Abstract] [Full Text] [Related]

  • 3. Protein misfolding detected early in pathogenesis of transgenic mouse model of Huntington disease using amyloid seeding assay.
    Gupta S, Jie S, Colby DW.
    J Biol Chem; 2012 Mar 23; 287(13):9982-9989. PubMed ID: 22187438
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. From Seeds to Fibrils and Back: Fragmentation as an Overlooked Step in the Propagation of Prions and Prion-Like Proteins.
    Marrero-Winkens C, Sankaran C, Schätzl HM.
    Biomolecules; 2020 Sep 10; 10(9):. PubMed ID: 32927676
    [Abstract] [Full Text] [Related]

  • 7. Protein Misfolding Diseases.
    Hartl FU.
    Annu Rev Biochem; 2017 Jun 20; 86():21-26. PubMed ID: 28441058
    [Abstract] [Full Text] [Related]

  • 8. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases.
    Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, Soto C.
    J Neurosci; 2010 Mar 31; 30(13):4528-35. PubMed ID: 20357103
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Alzheimer disease and the prion disorders amyloid beta-protein and prion protein amyloidoses.
    Price DL, Borchelt DR, Sisodia SS.
    Proc Natl Acad Sci U S A; 1993 Jul 15; 90(14):6381-4. PubMed ID: 8101988
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Protein conformational misfolding and amyloid formation: characteristics of a new class of disorders that include Alzheimer's and Prion diseases.
    Thompson AJ, Barrow CJ.
    Curr Med Chem; 2002 Oct 15; 9(19):1751-62. PubMed ID: 12369885
    [Abstract] [Full Text] [Related]

  • 13. Process, Outcomes and Possible Elimination of Aggregation with Special Reference to Heme Proteins; Likely Remediations of Proteinopathies.
    Furkan M, Khan RH.
    Curr Protein Pept Sci; 2020 Oct 15; 21(6):573-583. PubMed ID: 32013844
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. In Vitro Conversion Assays Diagnostic for Neurodegenerative Proteinopathies.
    Singh S, DeMarco ML.
    J Appl Lab Med; 2020 Jan 01; 5(1):142-157. PubMed ID: 31811072
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Prion-like disorders and Transmissible Spongiform Encephalopathies: An overview of the mechanistic features that are shared by the various disease-related misfolded proteins.
    Eraña H, Venegas V, Moreno J, Castilla J.
    Biochem Biophys Res Commun; 2017 Feb 19; 483(4):1125-1136. PubMed ID: 27590581
    [Abstract] [Full Text] [Related]

  • 20. Prion-like aggregates: infectious agents in human disease.
    Westermark GT, Westermark P.
    Trends Mol Med; 2010 Nov 19; 16(11):501-7. PubMed ID: 20870462
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.